Company Overview and News

10
Why Graco's (GGG) Stock Seems a Sensible Investment Bet?

2018-06-19 zacks
Adding Graco Inc. (GGG - Free Report) stock to your portfolio at the moment will be a promising investment move. The company currently sports a Zacks Rank #1 (Strong Buy) and its earnings per share are predicted to grow by 10.3% in the next three to five years. What’s Driving Graco’s Growth Prospects? The upsurge in the U.S. manufacturing sector will likely prove beneficial for Graco, as the company generates almost 60% revenues from this domain.
IR.WI GGG IR IEX AIT INGERRAND 500210

6
Ingersoll (IR) Hikes Dividend by 18% to Reward Shareholders

2018-06-12 zacks
Ingersoll-Rand Plc (IR - Free Report) recently raised its quarterly dividend by 18% year over year to 53 cents per share or $2.12 on an annualized basis. The increased sum will be paid on Sep 28 to shareholders on record as of Sep 7. The industrial goods manufacturer has been paying uninterrupted quarterly cash dividends since 1919 and annual dividends since 1910. A steady payout is part of the long-term strategy of Ingersoll to provide attractive risk-adjusted returns to its stockholders.
IR.WI AIMC IR IEX KAMN INGERRAND 500210

60
Ingersoll (IR)-Mitsubishi JV Starts Rolling Out Products

2018-05-18 zacks
The joint venture (JV) of Ingersoll-Rand Plc (IR - Free Report) and Mitsubishi Electric Corporation has started to roll out state-of-the-art products for customers across the globe. Leveraging on the extensive technological knowhow and applications expertise of the JV partners, the products have created a niche market in the United States and some Latin American countries. The joint venture that operates under the brand name, Mitsubishi Electric Trane HVAC, manufactures variable-speed mini-split, multi-split, and VRF (Variable Refrigerant Flow) air conditioners and heat pumps for homes, light commercial and commercial applications.
KAI DUKH IR.WI MIELF KAMN DUK MEL MIELY AIMC IR 6503 AMAT INGERRAND 500210

15
Regal Beloit vs. IDEX: Which Stock to Bet Post Q1 Earnings?

2018-05-11 zacks
With first-quarter earnings drawing to a close, industry peers are doing various analysis and comparisons to gauge the underlying metrics and relative performance. Let us perform a similar comparative analysis between two stocks in the Zacks Industrial Products sector — Regal Beloit Corporation (RBC - Free Report) and IDEX Corporation (IEX - Free Report) — to pick the better investment option. Earnings Scoresheet Regal Beloit reported decent first-quarter 2018 results, supported by strong organic sales growth and favorable foreign currency translation impact.
IR.WI AOS IR IEX INGERRAND 500210

449
The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes

2018-05-11 zacks
Chicago, IL – May 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Seagate Technology plc (STX - Free Report) , Grafton Group plc Grafton Units (GROUF - Free Report) , Ingersoll-Rand Plc (IR - Free Report) and Alkermes plc (ALKS - Free Report) .
IR.WI LRCX ALKS GROUF STX GFTU GROUY IR AMAT AAOI INGERRAND 500210

28
4 Top Stocks to Buy As Irish Economy Gathers Steam

2018-05-10 zacks
Ireland, the fastest growing economy of the European Union, has gone from strength to strength in the past few years. The Irish labor market remains tight currently as its unemployment is near a 10-year low. Also, the EU has been upbeat about the growth prospects of the Irish economy in the years to come.
IR.WI ALKS GROUY IR GROUF STX INGERRAND GFTU 500210

6
Is Guggenheim Mid-Cap Core ETF (CZA) a Hot ETF Right Now?

2018-05-07 zacks
Making its debut on 04/02/2007, smart beta exchange traded fund Guggenheim Mid-Cap Core ETF (CZA - Free Report) provides investors broad exposure to the Mid Cap ETFs category of the U.S. equity market.
IR.WI RF.PRB RF.PRA IR RF CZA URBN INGERRAND KEY 500210

9
IDEX (IEX) Q1 Earnings Beat on Solid Organic Growth, View Up

2018-05-01 zacks
IDEX Corporation (IEX - Free Report) reported strong first-quarter 2018 results with all-time high revenues, operating income and earnings driven by healthy organic growth and diligent execution of operational plans. GAAP earnings for the reported quarter were $99 million or $1.27 per share compared with $75.9 million or 99 cents per share in the year-earlier quarter. The year-over-year improvement was primarily attributable to top-line growth.
ATLKY IR.WI LRCX ATLKF ATTLF AIMC IR IEX ATLCY TEL INGERRAND 500210

73
Ingersoll (IR) Looks Good: Stock Adds 5.9% in Session

2018-04-26 zacks
Ingersoll-Rand Plc (IR - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $80.39 –$86.36 in the past one-month time frame, witnessed a sharp increase yesterday.
[DXPE] IR.WI DXPE 7018 CME IR ADM INGERRAND 500210

1
Ingersoll-Rand PLC Stock Pops on Strong Q1 Results

2018-04-25 investorplace
Ingersoll-Rand PLC (NYSE:IR) stock was up on Wednesday following the release of a positive earnings report for the first quarter of the year.
IR.WI IR INGERRAND 500210

1
Ingersoll-Rand Plc (IR) Q1 2018 Results - Earnings Call Transcript

2018-04-25 seekingalpha
Good morning. Welcome to the Ingersoll-Rand First Quarter 2018 Earnings Conference Call. My name is Chris, and I will be your operator. The call will begin in a few moments with a speaker remarks and then a Q&A session. All lines are on mute.
IR.WI IR INGERRAND 500210

8
Ingersoll (IR) Beats Both Q1 Earnings & Revenue Estimates

2018-04-25 zacks
Industrial goods manufacturer Ingersoll-Rand Plc (IR - Free Report) started 2018 on a positive note, reporting solid first-quarter 2018 results with adjusted earnings from continuing operations of 70 cents per share compared with 57 cents in the year-earlier quarter. The healthy year-over-year improvement in adjusted earnings was largely driven by top-line growth. Adjusted earnings comfortably beat the Zacks Consensus Estimate of 62 cents.
KAI IR.WI GGG AIMC IR DVN INGERRAND 500210

1
Ingersoll (IR) Beats Q1 Earnings on Healthy Organic Growth

2018-04-25 zacks
With a diverse portfolio of industrial and commercial products, Ingersoll-Rand Plc (IR - Free Report) is a premier player in the industrial goods market. This Dublin, Ireland-based firm has a solid foundation of global brands with a leading market share in all major product lines. After the divestiture of the commercial and residential security businesses, IR has been diligently focusing on improving the efficiencies and capabilities of its core businesses.
IR.WI IR INGERRAND 500210

81
Cramer's lightning round: Buy Ingersoll-Rand on economic tailwinds

2018-04-23 cnbc
Ingersoll-Rand PLC: "Oh, I like Ingersoll-Rand. It's precisely the kind of cyclical industrial that works well at this phase of the tightening cycle."
IR.WI BGX ALB AIMT BGLF BX ZBRA NEWTZ BGB IR NEWT INGERRAND NEWTL 500210

64
Can Higher Climate Revenues Buoy Ingersoll (IR) Q1 Earnings?

2018-04-23 zacks
Industrial goods manufacturer Ingersoll-Rand Plc (IR - Free Report) is scheduled to report first-quarter 2018 financial results before the opening bell on Apr 25. The company is likely to report higher revenues in the quarter in both the operating segments due to healthy growth dynamics. Whether this could result in higher earnings for the quarter remains to be seen. Top-Line Expansion Ingersoll is focusing on improving the efficiencies and capabilities of products and services within its core businesses.
IR.WI CATR CAT IR ATI PRLB CSGP INGERRAND 500210

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...